NK cell marker gene-based model shows good predictive ability in prognosis and response to immunotherapies in hepatocellular carcinoma

[1]  M. Kanehisa,et al.  KEGG for taxonomy-based analysis of pathways and genomes , 2022, Nucleic Acids Res..

[2]  Q. Cheng,et al.  Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts , 2022, Journal of Hematology & Oncology.

[3]  Sophie Curio,et al.  The unique role of innate lymphoid cells in cancer and the hepatic microenvironment , 2022, Cellular & Molecular Immunology.

[4]  F. Re,et al.  TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells , 2022, Science Immunology.

[5]  T. Greten,et al.  Interventional radiology meets immuno-oncology for hepatocellular carcinoma. , 2022, Journal of hepatology.

[6]  K. Luo,et al.  Visualization of natural killer cell-mediated killing of cancer cells at single-cell resolution in live zebrafish. , 2022, Biosensors & bioelectronics.

[7]  Jakob Nikolas Kather,et al.  Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. , 2022, Journal of hepatology.

[8]  K. Ainslie,et al.  Microparticle Delivery of a STING Agonist Enables Indirect Activation of NK Cells by Antigen-Presenting Cells. , 2022, Molecular pharmaceutics.

[9]  Lin Zhang,et al.  Single-Cell Transcriptomic Analysis Reveals Macrophage–Tumor Crosstalk in Hepatocellular Carcinoma , 2022, Frontiers in Immunology.

[10]  K. Sartorius,et al.  Resident Immune Cells of the Liver in the Tumor Microenvironment , 2022, Frontiers in Oncology.

[11]  K. Yamagata,et al.  NAD+ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity , 2022, Hepatology.

[12]  Doan Y. Dao,et al.  Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma , 2022, Nature Reviews Gastroenterology & Hepatology.

[13]  Hailong Wu,et al.  Liver Regeneration in Chronic Liver Injuries: Basic and Clinical Applications Focusing on Macrophages and Natural Killer Cells , 2022, Cellular and molecular gastroenterology and hepatology.

[14]  T. Luedde,et al.  Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. , 2022, Journal of hepatology.

[15]  Aileen W. Li,et al.  A vaccine targeting resistant tumours by dual T cell plus NK cell attack , 2022, Nature.

[16]  É. Vivier,et al.  Advancing natural killer therapies against cancer , 2022, Cell.

[17]  A. Fathi,et al.  Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma , 2022, Cancers.

[18]  V. Mazzaferro,et al.  Immunotherapies for hepatocellular carcinoma , 2021, Nature Reviews Clinical Oncology.

[19]  L. Altucci,et al.  The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma , 2021, Cells.

[20]  P. Thall,et al.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.

[21]  X. Liu,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[22]  S. Asthana,et al.  A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.

[23]  F. Souza-Fonseca-Guimaraes,et al.  Bench to bedside: NK cells and control of metastasis. , 2017, Clinical immunology.

[24]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[25]  F. Marincola,et al.  Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus , 2015, Journal of Translational Medicine.

[26]  G. Gores,et al.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. , 2013, Gastroenterology.

[27]  L. Moretta.  NK cell-mediated immune response against cancer. , 2007, Surgical oncology.